Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating LBP-EC01, a recombinant bacteriophage cocktail, for treating acute uncomplicated urinary tract infection UTI caused by drug-resistant E. coli in females aged 18 to 75 years. This Phase 2 study includes an initial open-label lead-in with 30 patients to determine the best dosing regimen, followed by a larger blinded, randomized trial comparing LBP-EC01 plus antibiotic to placebo plus antibiotic in 288 patients who have an active UTI at the start of the study. The study consists of two parts. In Part 1, participants receive different dose regimens of LBP-EC01 administered intraurethrally on Days 1 and 2, combined with intravenous dosing and oral trimethoprimsulfamethoxazole TMPSMX from Days 1 to 3. Part 2 involves randomizing participants to receive either the selected LBP-EC01 dose regimen or placebo, both alongside oral TMPSMX, following the same dosing schedule. The study evaluates safety, tolerability, pharmacokinetics, and efficacy. Participants will provide urine, blood, and stool samples and attend scheduled visits for assessments. Researchers will measure LBP-EC01 levels in urine and blood, track clinical symptom resolution, and monitor microbiologic response up to Day 10 and maintenance of response up to 6 months. Safety and immunogenicity will also be monitored through adverse event reporting and laboratory tests during and after treatment.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.